NEW YORK, July 21 /PRNewswire-Asia-FirstCall/ -- American Oriental
Bioengineering, Inc. (NYSE: AOB), ('the Company' or 'AOBO'), a pharmaceutical
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter ('OTC')
products in China, today announced that AOBO was honorably elected as one of
the 'Top 20 Most Competitive Public Pharmaceutical Companies in China.' This
event was jointly organized by China's leading healthcare industry
associations, including the Chinese Pharmaceutical Enterprise Association and
its publication, Healthcare Executive Magazine, and China's Center for
Pharmaco-economics and Outcomes Research (CCPOR) at Beijing University, where
an awards ceremony was held today.
The 20 listed companies were selected from 132 Chinese pharmaceutical
companies listed in Shanghai, Shenzhen, Hong Kong, Singapore, New York or on
NASDAQ, as of February of this year. The selection criteria were based on the
companies' management capabilities, brand recognition, financial strength,
resource accessibility and quality of key team members.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental
Bioengineering, commented, 'We are very honored to receive this recognition by
the industry. This award speaks to the strength of our brand value and
competitiveness in the changing environment. We will continue to focus on
creating greater value for investors.'
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a China-based pharmaceutical
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter
products.
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements involve risks and uncertainties that may cause
actual results to differ materially from those set forth in these statements.
The economic, competitive, governmental, technological and other factors
identified in the Company's filings with the Securities and Exchange
Commission, including the Form 10-K for the year ended December 31, 2008, may
cause actual results or events to differ materially from those described in
the forward looking statements in this press release. The Company undertakes
no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
SOURCE American Oriental Bioengineering, Inc.
